Evidence map›Paper›PMID 40993729›Full record

ReviewMolecular cancer2025

Multifunctional gold nanoparticles: bridging detection, diagnosis, and targeted therapy in cancer.

Lianting Zhuang, Yi Lian, Tiantong Zhu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lianting Zhuang *Department of Ultrasound, Shengjing Hospital of China Medical University, Sanhao Street No.36, Shenyang, Liaoning Province, 110004, China.
Yi Lian *Department of Ultrasound, Shengjing Hospital of China Medical University, Sanhao Street No.36, Shenyang, Liaoning Province, 110004, China.
Tiantong ZhuDepartment of Ultrasound, Shengjing Hospital of China Medical University, Sanhao Street No.36, Shenyang, Liaoning Province, 110004, China. zhutt@sj-hospital.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains a leading global health challenge, responsible for millions of deaths annually. Conventional therapies are hindered by systemic toxicity, drug resistance, and ineffective targeting of the tumor microenvironment (TME). Gold nanoparticles (AuNPs) have emerged as promising tools in oncology, offering unique plasmonic properties, high biocompatibility, and the ability to be engineered for multifunctional applications. Recent advancements include sustainable biogenic synthesis methods, precision targeting through ligands, aptamers, and peptides, and the development of theranostic platforms that integrate multimodal imaging with controlled drug and gene delivery. Additionally, AuNPs are being combined with therapies like photothermal-immunotherapy to remodel the TME, enhancing therapeutic efficacy. This review explores AuNP applications in cancer detection, diagnosis, and therapy, focusing on targeted drug/gene delivery to overcome chemoresistance, advanced biosensing tools for early detection, hybrid nanocarrier designs for TME penetration, and combinatorial platforms for integrating photodynamic, chemotherapy, and radiotherapy. It also addresses key translational barriers, such as protein corona dynamics, long-term biodistribution concerns, and the scalability of green synthesis methods. To facilitate clinical adoption, it emphasizes the need for GMP-compatible manufacturing, personalized nanomedicine through computational design, and standardized safety assessments. AuNPs represent a transformative approach to precision oncology, with the potential to integrate diagnostic and therapeutic functions into adaptable, real-time systems.

Indexed as

GoldMetal NanoparticlesNeoplasmsAnimalsDrug Delivery SystemsHumansMolecular Targeted TherapyTheranostic NanomedicineTumor MicroenvironmentGoldBiogenic synthesisCancer theranosticsGold nanoparticlesTargeted drug deliveryTumor microenvironment (TME)

Identifiers

PMID40993729
PMCPMC12462202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.